Compare Fiverr International Ltd (FVRR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs ResMed Inc. — how do they compare? Fiverr International Ltd trades at $8.72 (market cap $310.61M), while ResMed Inc. trades at $229.08 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 102.7× Fiverr International Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and ResMed Inc. for 51 Days on average.
| FVRR | RMD | |
|---|---|---|
Market Cap | $310.61M | $31.89B |
Volume | 381,459 | 618,314 |
Sector | Media | Health |
52-Week High | $23.60 | $277.88 |
52-Week Low | $8.47 | $182.82 |
Typical Hold Time | 62 Days | 51 Days |
Enterprise Value | $63.00M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.70, up 2.35% on the day, but remains in a bearish technical trend with resistance near $9.00. Recent Q2 2026 earnings missed estimates, with revenue declining 10% year-over-year to $97.8 million, as AI adoption pressures lower-value freelance demand. The company maintains strong gross margins of 82% and trades at discounted valuations, including a P/E of 10.67 and P/S of 0.76. Cash flow trends show operational strength but negative net cash flow in 2025 and 2026.
The outlook is cautious; while valuations are low and profitability is improving, AI disruption and recent earnings misses pose significant headwinds. Analyst consensus is a 'Hold' with a $10.50 price target, reflecting near-term challenges but potential recovery if growth stabilizes. Key risks include competitive threats from AI tools and execution risks in adapting the business model.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
